Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Grössmann N. Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology No. 62. 2016 Authors' conclusions Venetoclax might be a treatment option for relapsed or refractory CLL patients with del(17p) as it has not been agreed upon any standard care for this indication. Nevertheless, a randomised controlled trial (RCT) will be necessary to compare safety and efficacy outcomes in order to enable the interpretation of the actual treatment effect. In addition, mature data is needed to evaluate the efficacy and safety of venetoclax, also in regard with long-term effects and potential resistant mechanisms. Indexing Status Subject indexing assigned by CRD MeSH Adult; Chromosome Aberrations; Chromosome Deletion; Humans; Leukemia, Lymphocytic, Chronic, B-Cell Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 AccessionNumber 32016001023 Date abstract record published 11/10/2016 |